Cargando…

Steroid-refractory chronic graft-versus-host disease: treatment options and patient management

Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD is associated with poor health-related quality of life and substantial disease burden. While corticosteroids with or without calcin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolff, Daniel, Fatobene, Giancarlo, Rocha, Vanderson, Kröger, Nicolaus, Flowers, Mary E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410585/ https://www.ncbi.nlm.nih.gov/pubmed/34218265 http://dx.doi.org/10.1038/s41409-021-01389-5

Ejemplares similares

Murine Models of Steroid Refractory Graft-versus-Host Disease
por: Toubai, Tomomi, et al.
Publicado: (2018)

Intramesenteric Steroid Treatment for Steroid- Refractory Gastrointestinal Graft Versus Host Disease
por: Bilgin, Aynur Uğur, et al.
Publicado: (2012)

Graft-versus-host disease in allogeneic transplantation: the good and the bad
por: Kröger, Nicolaus-Martin
Publicado: (2022)

Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease
por: Gunes, Gursel, et al.
Publicado: (2015)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease
por: Donadel, Camila Derminio, et al.
Publicado: (2023)

Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease
por: Abedin, Sameem, et al.
Publicado: (2020)

Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation
por: Fatobene, Giancarlo, et al.
Publicado: (2019)

Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
por: Fatobene, Giancarlo, et al.
Publicado: (2021)

Telehealth in hematopoietic cell transplantation: perspective from patients at a public hospital in Brazil
por: Cordeiro, Ana, et al.
Publicado: (2022)

Treatment and unmet needs in steroid-refractory acute graft-versus-host disease
por: Malard, Florent, et al.
Publicado: (2020)

Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease
por: Kim, Hyun Min, et al.
Publicado: (2023)

Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease
por: Furlong, Terry, et al.
Publicado: (2009)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape
por: Greinix, Hildegard T., et al.
Publicado: (2022)

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2020)

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2021)

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
por: Kaurinovic, Martina, et al.
Publicado: (2022)

Tozinameran: Worsening of chronic graft-versus-host disease and steroid-refractory immune thrombocytopenia: 2 case reports
Publicado: (2022)

Pneumocystis jirovecii Pneumonia during Brentuximab Vedotin Therapy: A Case Report and Literature Review
por: Ferreira, Aliana Meneses, et al.
Publicado: (2019)

Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience
por: De Jong, Cornelis N., et al.
Publicado: (2017)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
por: Kim, Haesook T., et al.
Publicado: (2022)

Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease
por: Rager, Alison, et al.
Publicado: (2010)

Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients
por: Grabner, Michael, et al.
Publicado: (2021)

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis
por: Socié, Gerard, et al.
Publicado: (2023)

Comparison of Characteristics and Laboratory Tests of COVID 19-Hematological Patients from France and Brazil: Identification of Prognostic Driven Profiles
por: Alves, Lucas Bassolli de Oliveira, et al.
Publicado: (2021)

Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation
por: Park, Joo Han, et al.
Publicado: (2014)

Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease
por: Shen, Meng-Zhu, et al.
Publicado: (2021)

Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease Using Commercial Mesenchymal Stem Cell Products
por: Murata, Makoto, et al.
Publicado: (2021)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei, Cong, et al.
Publicado: (2021)

Treatment of chronic graft-versus-host disease: Past, present and future
por: Martin, Paul J., et al.
Publicado: (2011)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
por: Hinterlang, Mélanie, et al.
Publicado: (2022)

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022)

Data-driven grading of acute graft-versus-host disease
por: Bayraktar, Evren, et al.
Publicado: (2023)

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
por: Ong, Jian Chun Matthew, et al.
Publicado: (2023)

GVHD treatment with extracorporeal photopheresis in Brazil: a national survey
por: Fatobene, Giancarlo, et al.
Publicado: (2022)

Similar Outcomes in Early-Failure Steroid-Dependent Compared to Upfront Steroid Refractory Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplant
por: Patel, Dilan A., et al.
Publicado: (2021)

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Hengwei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lmhgt6uktddqo294f5ptfrbo9s